A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study the effect of LY2189265 on how the body absorbs and
processes a Type 2 Diabetes Mellitus (T2DM) drug (sitagliptin) and how sitagliptin affects
LY2189265 when they are taken together.
The duration of participation in this study is expected to be approximately 61 days. The
study requires 2 clinic confinements (one of 2 nights and one of 19 nights duration).
The study involves 3 injections, subcutaneous, of 1.5 milligrams (mg) LY2189265 and 18 daily
doses of 100 mg sitagliptin tablets administered orally.